EUVIMEDEUVIMED entdecken
Multizentrische StudieÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Miri Assayag, Irit Avivi, Moshe E Gatt

Acta Haematologica · 02.10.2024 · 148 (4) · 419-426

DOI: 10.1159/000541594 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Haematologica, online erschienen am 02.10.2024. Verfasst von Eyal Lebel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Treatment for relapsed/refractory AL amyloidosis (AL) is an unmet need. The safety and efficacy of belantamab mafodotin (BLM) in multiple myeloma are known, whereas in AL data are limited.

Methods

We report a multi-center cohort of AL patients receiving BLM, and review all previous data on BLM therapy in AL.

Results

Twelve patients with a median of 3 (range 2–9) prior lines of therapy were included. The overall hematological response rate (ORR) was 75% (9/12), including 5 complete responses. Six of the 10 evaluable patients had organ responses. The median event-free survivals/overall survivals were 22.3 and 28.8 months, respectively. Grade 3 toxicities were mostly infections and keratopathy, occurring in 7/12 (58%). Hematological toxicities were rare. No grade 4/5 toxicities occurred. The review of the previous series reveals BLM provides an ORR of 60–83% with similar rates of corneal toxicity.

Conclusion

BLM, being an off-the-shelf therapy, with acceptable toxicity even in frail patients, may be a valuable option in AL, with a high ORR, and a signal for durable responses and high-quality organ responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAntibodies, Monoclonal, HumanizedHumansMaleFemaleAgedMiddle AgedRecurrenceAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

AL amyloidosisAntibody drug conjugateBCMABelantamab mafodotinReal-world experience

Substanzen

belantamab mafodotinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
  • Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Zitieren

APA

Lebel, E., Vainstein, V., Milani, P., Palladini, G., Shragai, T., Lavi, N., Magen, H., Assayag, M., Avivi, I., & Gatt, M. E. (2024). Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature. Acta Haematologica, 148(4), 419-426. https://doi.org/10.1159/000541594

Vancouver

Lebel E, Vainstein V, Milani P, Palladini G, Shragai T, Lavi N, et al. Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature. Acta Haematologica. 2024;148(4):419-426. doi:10.1159/000541594

BibTeX
@article{Lebel2024,
  author = {Lebel, Eyal and Vainstein, Vladimir and Milani, Paolo and Palladini, Giovanni and Shragai, Tamir and Lavi, Noa and Magen, Hila and Assayag, Miri and Avivi, Irit and Gatt, Moshe E},
  title = {Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature},
  journal = {Acta Haematologica},
  year = {2024},
  volume = {148},
  number = {4},
  pages = {419--426},
  doi = {10.1159/000541594}
}
Kostenlos starten →